Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director

Accomplished biotech investor with a track record of successful company-building and exits to lead Angelini Ventures' international BioTech investment strategy 

Rome, Italy, 7 April 2025, Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces the appointment of Dr. Regina Hodits as Managing Director.

Dr. Hodits is one of Europe's most successful and respected biotech investors, bringing over two decades of experience in venture capital, company creation and strategic exits across the biotech sector. This senior appointment reflects Angelini Ventures' ambition to strengthen its presence in the sector and expand its international investment platform.

Based in Germany, Dr. Hodits will have a key leadership role to define Angelini Ventures' international BioTech investment strategy and partner with Paolo Di Giorgio, Thomas Thestrup, Fabrizio Calisti and Lola Buono to identify, evaluate and support breakthrough innovation across therapeutics and biotech AI. She brings deep sector expertise and a global network significantly expanding Angelini Ventures' access to high-quality deal flow and company-building capabilities while adding considerable value to our portfolio companies.

"Regina's scientific depth, extensive investment experience and exceptional track record in company-building make her a key addition to Angelini Ventures," said Paolo Di Giorgio, CEO and Managing Director of Angelini Ventures. "Her appointment strengthens our ability to identify and scale breakthrough biotech companies across Europe and North America. I'm looking forward to working closely with Regina as we expand our presence in key innovation hubs, back world-class ...